Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.
Industry at a
Crossroads:
The Rise of Digital in
the Outcome-Driven
R&D Organization
Accenture Life Sciences
Rethink Resha...
2
About the Research
Responses from 76 executives from the US and
Europe, representing diverse R&D organizations
within ph...
3
Key Findings
Copyright © 2016 Accenture All rights reserved.
Improving patient
outcomes ranked as
R&D’s #1 priority.
1
D...
Improving patient outcomes ranked
as R&D’s #1 priority
99%
report that
transforming their
R&D model to
be more patient
out...
5
Digital is a primary driver of becoming
more focused on patient outcomes
Copyright © 2016 Accenture All rights reserved....
6
Adoption of digital is inconsistent; half of respondents
are “all in” while others are exploring or waiting
Copyright © ...
7
Companies taking advantage of digital report
stronger performance in other R&D capabilities
Copyright © 2016 Accenture A...
8
Companies
at a
Crossroads
Together these findings suggest that
Life Sciences firms, and the R&D
organizations within the...
9
Stay Connected
linkedin.com/company/accenture_life_sciences
twitter.com/AccentureLifSci
accenture.com/lifesciencesblog
9...
Prochain SlideShare
Chargement dans…5
×

Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization

The biopharmaceutical industry is making a fundamental shift from a product focus to a patient and health system outcome focus. Digital solutions are injecting process improvement and additional value across the enterprise, from R&D to Commercial to Medical Affairs. It is this combination of changes that led Accenture to conduct a survey of top global R&D executives to see how these dynamics are impacting their organizations.

Livres associés

Gratuit avec un essai de 30 jours de Scribd

Tout voir

Livres audio associés

Gratuit avec un essai de 30 jours de Scribd

Tout voir

Les commentaires sont fermés

  • Soyez le premier à commenter

Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization

  1. 1. Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization Accenture Life Sciences Rethink Reshape Restructure …for better patient outcomes
  2. 2. 2 About the Research Responses from 76 executives from the US and Europe, representing diverse R&D organizations within pharmaceutical companies. Copyright © 2016 Accenture All rights reserved. Revenue of Respondent Organization Company Headquarters & Respondent Location United States 35 Germany 10 United Kingdom 11 France 10 Switzerland 10 30$1-5B $6-10B $11-25B >$25B 17 14 15 86% of respondents were the firm’s most senior R&D executive or senior divisional R&D executive. 14% of respondents were the firm’s senior R&D technology executive.
  3. 3. 3 Key Findings Copyright © 2016 Accenture All rights reserved. Improving patient outcomes ranked as R&D’s #1 priority. 1 Digital is a primary driver of becoming more focused on patient outcomes. 2 Adoption of digital is inconsistent; half of respondents are “all in” while others are exploring or waiting. 3 Companies taking advantage of digital report stronger performance in other R&D capabilities. 4
  4. 4. Improving patient outcomes ranked as R&D’s #1 priority 99% report that transforming their R&D model to be more patient outcome focused is critical or very important. 39% of respondents confirmed that focusing more on patient outcomes was already a key priority of R&D organizations. 49% stated that it should be the top priority. Developing more targeted therapies rather than broad based therapies Achieving faster time to market from First in Human to Approval Improving R&D productivity via increased quantity and quality of NMEs 37% 36% 36% Other key strategic imperatives to facilitate getting medicines to patients faster were identified as: Copyright © 2016 Accenture All rights reserved. 44 2015 2020 1
  5. 5. 5 Digital is a primary driver of becoming more focused on patient outcomes Copyright © 2016 Accenture All rights reserved. 25% of respondents said that digital will have the greatest impact on their firm’s ability to transform their R&D model to become more patient-focused. When asked in which areas digital technologies are having the greatest impact on the industry: 2 Improving R&D Productivity through Digitized processes 22% Enhancing Quality and Compliance to meeting changing regulatory requirements 18% Cost Reduction in R&D to improve productivity 12% Integrating or improving R&D Operations in key functional areas (Clinical/Reg/PV/Med Affairs) 11% *Other (Combined responses for four answers including: leveraging data to improve development, predictive R&D, home trials, and better collaboration) 12%*
  6. 6. 6 Adoption of digital is inconsistent; half of respondents are “all in” while others are exploring or waiting Copyright © 2016 Accenture All rights reserved. Despite the shared belief that digital can deliver sharper patient focus and improved outcomes, and the clear impact digital has had in transforming other sectors of pharma, there appears to be an even split among survey respondents about their own organization’s rate of adoption of digital. are “waiting and seeing” how digital is deployed before ramping up capability. 3% characterize their firm’s efforts as exploring how digital might improve their organizations. of executives confirm that their companies are already adopting digital. 42%55% 3 6
  7. 7. 7 Companies taking advantage of digital report stronger performance in other R&D capabilities Copyright © 2016 Accenture All rights reserved. Survey data tells us that the companies that have adopted digital reported better performance in R&D Capabilities. Those companies that have made a commitment to digital tend to underscore its importance with organizational changes. Percentage of respondents who answered “Strong” when asked about current performance in each area: 4 Harnessing real-world data analytics 60% 50% Core process redesign of TPP and CDP 55% 34% Using digital to make more effective use of Medical Science Liaisons (MSLs) 57% 47% Collaborating with other commercial organizations 60% 41% Adopting Digital Exploring Digital
  8. 8. 8 Companies at a Crossroads Together these findings suggest that Life Sciences firms, and the R&D organizations within them, are AT A CROSSROADS in terms of their digital adoption and enablement. Copyright © 2016 Accenture All rights reserved.
  9. 9. 9 Stay Connected linkedin.com/company/accenture_life_sciences twitter.com/AccentureLifSci accenture.com/lifesciencesblog 9Copyright © 2016 Accenture All rights reserved. Authors: Nicole F. Cohen – nicole.f.cohen@accenture.com Thomas K. Kelly, Jr. – thomas.k.kelly.jr@accenture.com To learn more, visit: accenture.com/ rd-journey

×